loading...| Preferred Name |
Alteplase |
|
| Synonyms |
|
|
| Definitions |
A recombinant therapeutic agent which is chemically identical to or similar to endogenous tissue plasminogen activator (tPA). tPA is a serine protease which converts plasminogen to plasmin, a fibrinolytic enzyme. Upon administration, alteplase increases plasmin enzymatic activity, resulting in hyperfibrinolysis and potential dissolution of a thrombus or embolism. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C39607 |
|
| ALT_DEFINITION |
A form of tissue plasminogen activator that is made in the laboratory. It helps dissolve blood clots and is used to treat heart attacks, strokes, and clots in the lungs. It is also being studied in the treatment of cancer. It is a type of systemic thrombolytic agent. |
|
| CAS_Registry |
105857-23-6 |
|
| code |
C39607 |
|
| Contributing_Source |
FDA |
|
| definition |
A recombinant therapeutic agent which is chemically identical to or similar to endogenous tissue plasminogen activator (tPA). tPA is a serine protease which converts plasminogen to plasmin, a fibrinolytic enzyme. Upon administration, alteplase increases plasmin enzymatic activity, resulting in hyperfibrinolysis and potential dissolution of a thrombus or embolism. |
|
| FDA_UNII_Code |
1RXS4UE564 |
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C173383 |
|
| Is_Related_To_Endogenous_Product | ||
| label |
Alteplase |
|
| Legacy Concept Name |
Recombinant_Tissue_Plasminogen_Activator |
|
| NCI_Drug_Dictionary_ID |
42033 |
|
| PDQ_Closed_Trial_Search_ID |
42033 |
|
| PDQ_Open_Trial_Search_ID |
42033 |
|
| Preferred_Name |
Alteplase |
|
| prefixIRI |
NCIT:C39607 |
|
| prefLabel |
Alteplase |
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance |
|
| UMLS_CUI |
C0032143 |
|
| subClassOf |